Company: DNLI
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001714899-25-000193
Chunk: 182

Company: Denali Therapeutics Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 182
---
2024, respectively1,793 1,768 Additional paid-in capital2,846,278 2,764,880 Accumulated other comprehensive income1,101 2,020 Accumulated deficit(1,922,975)(1,538,984)Total stockholders' equity926,197 1,229,684 Total liabilities and stockholders’ equity$1,055,621 $1,374,180 

See accompanying notes to unaudited condensed consolidated financial statements.

3

Table of Contents

Denali Therapeutics Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands, except share and per share amounts)

Three Months Ended September 30,Nine Months Ended September 30,2025202420252024Operating expenses:Research and development$101,950 $98,238 $320,873 $296,653 General and administrative35,484 24,949 97,104 75,379 Total operating expenses137,434 123,187 417,977 372,032 Gain from divestiture of small molecule programs— — — 14,537 Loss from operations(137,434)(123,187)(417,977)(357,495)Interest and other income, net10,532 15,995 33,986 49,475 Net loss$(126,902)$(107,192)$(383,991)$(308,020)Net loss per share, basic and diluted$(0.74)$(0.63)$(2.24)$(1.89)Weighted average number of shares outstanding, basic and diluted172,421,492169,456,988171,702,183162,589,325Comprehensive lossNet loss$(126,902)$(107,192)$(383,991)$(308,020)Other comprehensive income (loss):Net unrealized gain (loss) on marketable securities, net of tax162 8,188 (919)4,886 Comprehensive loss$(126,740)$(99,004)$(384,910)$(303,134)

See accompanying notes to unaudited condensed consolidated financial statements.

4

Table of Contents

Denali Therapeutics Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

(In thousands, except share amounts)    

Common StockAdditional Paid-in CapitalAccumulated Other Comprehensive